Effect of Mini-Dose Ready-to-Use Liquid Glucagon on Preventing Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

Who Took Part

The age groups tagged for this paper are adults.

Participants were to undertake their usual aerobic exercise at moderate to high intensity for 30 to 75 min in real-world settings.

How the Study Was Run

The researchers set it up as a randomized, open-label, placebo-controlled and crossover study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Glucagon study: the participants and staff both knew the treatment.

Some participants received a placebo instead of Glucagon, giving a reference point.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

Data were analyzed for incidence of level 1 hypoglycemia based on self-monitoring blood glucose and for various secondary and exploratory end points.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 1, Exercise, Glucagon, Hypoglycemia, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, open-label and placebo-controlled study of Glucagon.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Diabetes care), a journal based in United States.

More context: the Glucagon compound page, all human trials.